gutflix
GI learning, personalised

Summary

COMBINED CHEMOTHERAPY AND PHOSPHORUS-32 MICROPARTICLE INTRA-TUMORAL IMPLANTATION IN PATIENTS WITH LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA: AN AUSTRALIA-NEW ZEALAND (ANZ) EXPERIENCE

Nam Quoc Nguyen

UEG Week Copenhagen 2023 | Poster

Pancreas

October 15, 2023

A two-centre retrospective study of 49 patients with locally advanced pancreatic cancer treated with combination chemotherapy and EUS-guided phosphorus-32 microparticle implantation reported 96% local disease control at 12 weeks, 31% tumor downstaging, 18.4% successful resection rate, and median overall survival of 16 months.

KEY POINTS

- 49 patients (median age 72 years) with non-metastatic unresectable or borderline resectable locally advanced pancreatic cancer received either FOLFIRINOX (n=19) or gemcitabine and nab-paclitaxel (n=30) combined with EUS-guided intratumoral phosphorus-32 microparticle implantation between August 2017 and January 2023
- Technical success of phosphorus-32 implantation was 100% with no acute complications; median microparticle volume injected was 1mL into tumors with median longest diameter 29.5mm
- At 12 weeks post-implant, local disease control was 96%; 15 patients (31%) had tumor downstaging to theoretically resectable disease, and 9 patients (18.4%) underwent successful resection with 6 of 9 achieving R0 resection
- Median overall survival from diagnosis was 16 months with no significant difference between FOLFIRINOX (14.6 months) and gemcitabine/nab-paclitaxel groups (16.6 months, p=0.259); at median follow-up of 20 months, 55% had disease progression
- The authors describe this as the largest reported Australia and New Zealand cohort with this combined therapy and state that comparative studies against standard therapy are warranted

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/e1cf2d26-743c-11ee-8436-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.